Abstract
Although multiple actionable mutations and translocations have been identified for non-small cell lung cancer (NSCLC), these have been almost exclusively found in adenocarcinoma. The search for molecular targets and their corresponding predictive biomarkers continues for squamous cell lung cancer, but clinical trials have been disappointing. Immune therapy with PD-L1 expression as a predictive biomarker has demonstrated greater promise for squamous cell carcinoma than actionable mutations and translocations.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Gandara DR, Hammerman PS, Sos ML, Lara PN Jr, Hirsch FR. Squamous cell lung cancer: from tumor genomics to cancer therapeutics. Clin Cancer Res. 2015;21(10):2236–43.
Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–21.
Genova C, Rijavec E, Grossi F. Recent advances in squamous non-small cell lung cancer: evidence beyond predictive biomarkers. Expert Rev Anticancer Ther. 2016;16(1):1–4.
Heist RS, Sequst LV, Engelman JA. Genetic changes in squamous cell cancer: a review. J Thorac Oncol. 2012;7(5):924–33.
Sundar R, Cho BC, Brahmer JR, et al. Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol. 2015;7(2):85–96.
Clinical Lung Cancer Genome Progect (CLCGP), Network Genomic Medicine (NGM). A genomics-based classification of human lung tumors. Sci Transl Med. 2013;5:209ra153.
Kim Y, Hammerman PS, Kim J, et al. Integratice and comparative genomic analysis of lung squamous cell carcinoma in east Asian patients. J Clin Oncol. 2014;32:121–8.
Chan BA, Hughes BGM. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res. 2015;4(1):36–54.
Ferone G, Sing J, Sutherland KD, et al. SOX2 is the determining oncogenic switch in promoting lung squamous cell carcinoma from different cells of origin. Cancer Cell. 2016;30(4):519–32.
Miller RA, Miller TN, Cagle PT. PD-1/PD-L1, only a piece of the puzzle. Arch Pathol Lab Med. 2016;140(11):1187–8.
Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015;125(9):3384–91.
Brahmer JR, Tykodi SS, Chow LQ, et al. Safery and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–65.
Topalian SL, Hodi FS, Brahmer JR, et al. Sahety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;336(26):2443–54.
McLaughlin J, Han G, Schalper KA, et al. Heterogeneity of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol. 2016;2(1):46–54.
Garassino M, Besse B, Janne P, Christof D, Peters S. Atezolizumab as 1L therapy of advanced NSCLC in PD-L1 selected patients: updated ORR, PFS, OS data from the BRICH study. JTO WCLC. 2016;12:S130.
Reck M, Rodruguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–33.
Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–50.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG
About this chapter
Cite this chapter
Miller, R.A., Cagle, P.T. (2018). Predictive Biomarkers for Squamous Cell Carcinoma. In: Cagle, P., et al. Precision Molecular Pathology of Lung Cancer. Molecular Pathology Library. Springer, Cham. https://doi.org/10.1007/978-3-319-62941-4_13
Download citation
DOI: https://doi.org/10.1007/978-3-319-62941-4_13
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-62940-7
Online ISBN: 978-3-319-62941-4
eBook Packages: MedicineMedicine (R0)